EP2865403A1 — Inhaler
Assigned to Novartis AG · Expires 2015-04-29 · 11y expired
What this patent protects
The invention deals with an inhaler (1) comprising a capsule housing (2) for containing a medicament capsule (4), an airflow path (6) through which air flows during an airflow event from at least one air inlet (8) to an outlet (10), the airflow path (6) passing through the capsul…
USPTO Abstract
The invention deals with an inhaler (1) comprising a capsule housing (2) for containing a medicament capsule (4), an airflow path (6) through which air flows during an airflow event from at least one air inlet (8) to an outlet (10), the airflow path (6) passing through the capsule housing (2), the capsule housing (2) being defined by at least one wall (22) and configured such that when a capsule (4) is located in the capsule housing (4) and sufficient air flows along the airflow path (6) through the capsule housing (2), the capsule (4) moves within the capsule housing (2). The inhaler includes a first sensor (16) which is arranged on the inhaler (1) and able to detect the movement of the capsule (4) within the capsule housing (2) and generate a first signal indicative of said movement and an output from which the signal can be accessed by an external device, such as a computer.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.